Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Joseph Gligorov et al.|Annals of Oncology|2021Cited by 724
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in ItalyFrancesco Cognetti, Sandro Barni, Daniela Cianniello et al.|npj Breast Cancer|2021Cited by 29
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical OncologyFederica Miglietta, Stefania Gori, Michela Cinquini et al.|The Breast|2022Cited by 16
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studiesFederica Miglietta, Valentina Guarneri, Maria Vittoria Dieci et al.|European Journal of Cancer|2023Cited by 14
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Maria Vittoria Dieci, Moira Ragazzi et al.|Clinical Cancer Research|2023Cited by 13